Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer.

Literature DB >> 24790399

Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer.

Abstract

Overexpression of human epidermal growth factor receptor 2 (HER2) is an important factor in cancer survival, proliferation, and metastasis. Agents that target HER2-positive tumors are used with traditional chemotherapies, with other targeted therapies, or as monotherapy to treat metastatic breast cancers.

Entities: Disease Gene

Year: 2014 PMID： 24790399 PMCID： PMC4005117

Source DB: PubMed Journal: P T ISSN： 1052-1372

28 in total

1. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

Authors: Ian E Krop; Patricia LoRusso; Kathy D Miller; Shanu Modi; Denise Yardley; Gladys Rodriguez; Ellie Guardino; Michael Lu; Maoxia Zheng; Sandhya Girish; Lukas Amler; Eric P Winer; Hope S Rugo
Journal: J Clin Oncol Date: 2012-05-29 Impact factor: 44.544

Review 2. The role of HER2 in cancer therapy and targeted drug delivery.

Authors: Wanyi Tai; Rubi Mahato; Kun Cheng
Journal: J Control Release Date: 2010-04-10 Impact factor: 9.776

3. Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors: Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal: N Engl J Med Date: 2012-10-01 Impact factor: 91.245

4. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.

Authors: Gunter von Minckwitz; Kathrin Schwedler; Marcus Schmidt; Jana Barinoff; Christoph Mundhenke; Tanja Cufer; Eduard Maartense; Felix E de Jongh; Klaus H Baumann; Joachim Bischoff; Nadia Harbeck; Hans-Joachim Lück; Nicolai Maass; Christoph Zielinski; Michael Andersson; Robert C Stein; Valentina Nekljudova; Sibylle Loibl
Journal: Eur J Cancer Date: 2011-07-07 Impact factor: 9.162

5. Lapatinib - Member of a New Generation of ErbB-Targeting Drugs.

Authors: Michael Untch; Hans-Joachim Lück
Journal: Breast Care (Basel) Date: 2010-04-26 Impact factor: 2.860

Review 6. The role of HER2 in angiogenesis.

Authors: R Kumar; R Yarmand-Bagheri
Journal: Semin Oncol Date: 2001-10 Impact factor: 4.929

7. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

Authors: José Baselga; Karen A Gelmon; Shailendra Verma; Andrew Wardley; Pierfranco Conte; David Miles; Giulia Bianchi; Javier Cortes; Virginia A McNally; Graham A Ross; Pierre Fumoleau; Luca Gianni
Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544

8. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors: D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal: Science Date: 1987-01-09 Impact factor: 47.728

9. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen.

Authors: A L Schechter; D F Stern; L Vaidyanathan; S J Decker; J A Drebin; M I Greene; R A Weinberg
Journal: Nature Date: 1984 Dec 6-12 Impact factor: 49.962

10. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.

Authors: Lee S Schwartzberg; Lee S Schwarzberg; Sandra X Franco; Allison Florance; Lisa O'Rourke; Julie Maltzman; Stephen Johnston
Journal: Oncologist Date: 2010-02-15

4 in total

Review 1. Nanotechnology as a Delivery Tool for Precision Cancer Therapies.

Authors: Bhawna Sharma; Rachael M Crist; Pavan P Adiseshaiah
Journal: AAPS J Date: 2017-10-10 Impact factor: 4.009

Review 2. HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance.

Authors: Babak Nami; Zhixiang Wang
Journal: Cancers (Basel) Date: 2017-04-26 Impact factor: 6.639

3. Influence of supercritical fluid extraction parameters in preparation of black chokeberry extracts on total phenolic content and cellular viability.

Authors: Jonathan Wenzel; Lihua Wang; Sebastian Horcasitas; Alyssa Warburton; Scott Constine; Anna Kjellson; Kirsten Cussans; Michelle Ammerman; Cheryl S Samaniego
Journal: Food Sci Nutr Date: 2020-05-26 Impact factor: 2.863

Review 4. The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer.

Authors: Michaela Poliaková; Daniel M Aebersold; Yitzhak Zimmer; Michaela Medová
Journal: Mol Cancer Date: 2018-02-19 Impact factor: 27.401

4 in total